XML 51 R21.htm IDEA: XBRL DOCUMENT v3.20.1
Investment in Unconsolidated Entities (Tables)
12 Months Ended
Dec. 31, 2019
Neuro Partners LLC and CGK [Member]  
Schedule of Equity Method Investments [Line Items]  
Equity Method Investment Summarized Financial Information
The following tables present the aggregation of summarized financial information of NeuroPartners LLC and CGK:

Neuro Partners LLC and CGK Combined Condensed Income Statement Information
 
  
  
Year Ended
December 31,
 
  
2019
  
2018
 
       
Patient revenue
 
$
1,020,000
  
$
1,141,000
 
         
Net income
 
$
303,000
  
$
590,000
 
         
USNC’s equity in income of Neuro Partners LLC and CGK
 
$
92,000
  
$
181,000
 

Neuro Partners LLC and CGK Combined Condensed Balance Sheet Information
 
  
  
December 31,
 
  
2019
  
2018
 
       
Current assets
 
$
163,000
  
$
304,000
 
         
Noncurrent assets
  
807,000
   
1,064,000
 
         
Total assets
 
$
970,000
  
$
1,368,000
 
         
Current liabilities
 
$
380,000
  
$
399,000
 
         
Noncurrent liabilities
  
593,000
   
924,000
 
         
(Deficit) equity
  
(3,000
)
  
45,000
 
         
Total liabilities and (deficit) equity
 
$
970,000
  
$
1,368,000
 
FOP [Member]  
Schedule of Equity Method Investments [Line Items]  
Equity Method Investment Summarized Financial Information
The following tables present the summarized financial information of FOP:

FOP Condensed  Income Statement Information
   
    
  
Year Ended
December 31,
 
  
2019
  
2018
 
       
Patient revenue
 
$
1,922,000
  
$
2,953,000
 
         
Rental Income
 
$
543,000
  
$
1,252,000
 
         
Net loss
 
$
(1,377,000
)
 
$
(1,918,000
)
         
USNC’s equity in loss of FOP
 $
(334,000
) $
(465,000
)

FOP Condensed Balance Sheet Information
 
  
  
December 31,
 
   
2019
   
2018
 
         
Current assets
 
$
165,000
  
$
401,000
 
         
Noncurrent assets
  
1,202,000
   
16,570,000
 
         
Total assets
 
$
1,367,000
  
$
16,971,000
 
         
Current liabilities
 
$
4,003,000
  
$
3,974,000
 
         
Noncurrent liabilities
  
1,091,000
   
15,360,000
 
         
Equity
  
(3,727,000
)
  
(2,363,000
)
         
Total liabilities and equity
 
$
1,367,000
  
$
16,971,000
 
Boca Oncology Partners RE, LLC ("BOPRE") [Member]  
Schedule of Equity Method Investments [Line Items]  
Equity Method Investment Summarized Financial Information
The following tables present the summarized financial information of BOPRE:

BOPRE Condensed Income Statement Information
 
  
  
Years Ended December 31,
 
    
  
2019
  
2018
 
       
Rental Income
 
$
-
  
$
-
 
         
Net income (loss)
 
$
46,000
  
$
(4,000
)
         
USNC’s equity in income (loss) in BOPRE
 
$
11,000
  
$
(1,000
)

BOPRE Condensed Balance Sheet Information
 
  

 
December 31,
 
  
2019
  
2018
 
       
Current assets
 
$
64,000
  
$
18,000
 
         
Noncurrent assets
  
935,000
   
935,000
 
         
Total assets
 
$
999,000
  
$
953,000
 
         
Current liabilities
 
$
-
  
$
-
 
         
Noncurrent liabilities
  
-
   
-
 
         
Equity
  
999,000
   
953,000
 
         
Total liabilities and equity
 
$
999,000
  
$
953,000
 
Medical Oncology Partners LLC [Member]  
Schedule of Equity Method Investments [Line Items]  
Equity Method Investment Summarized Financial Information
The following table presents the summarized financial information of MOP:

MOP Condensed  Consolidated Income Statement Information
 
  
 
Years Ended December 31,
 
     

2019
 
2018
 
     
Patient revenue
 
$
2,669,000
  
$
2,257,000
 
         
Net loss
 
$
(435,000
)
 
$
(282,000
)
         
USNC’s equity in loss in MOP
 
$
(156,000
)
 
$
(101,000
)

MOP Condensed Consolidated Balance Sheet Information
 
  
  
December 31,
 

 
2019
  2018 
       
Current assets
 
$
247,000
  
$
41,000
 
         
Noncurrent assets
  
807,000
   
159,000
 
         
Total assets
 
$
1,054,000
  
$
200,000
 
         
Current liabilities
 
$
1,907,000
  
$
1,002,000
 
         
Noncurrent liabilities
  
427,000
   
33,000
 
         
Deficit
  
(1,280,000
)
  
(835,000
)
         
Total liabilities and deficit
 
$
1,054,000
  
$
200,000
 
CB Oncology Partners LLC [Member]  
Schedule of Equity Method Investments [Line Items]  
Equity Method Investment Summarized Financial Information
The following table presents the summarized financial information of CBOP:

CBOP Condensed Income Statement Information
 
  
  
Years Ended December 31,
 
       
  
2019
  
2018
 
       
Patient revenue
 
$
1,637,000
  
$
956,000
 
         
Net loss
 
$
(418,000
)
 
$
(1,230,000
)
         
USNC’s equity in loss of CBOP
 
$
(101,000
)
 
$
(298,000
)

CBOP Condensed Balance Sheet Information
 
  
  
December 31,
 
  
2019
  
2018
 
       
Current assets
 
$
380,000
  
$
140,000
 
         
Noncurrent assets
  
4,869,000
   
-
 
         
Total assets
 
$
5,249,000
  
$
140,000
 
         
Current liabilities
 
$
3,026,000
  
$
1,618,000
 
         
Noncurrent liabilities
  
4,019,000
   
-
 
         
Deficit
  
(1,796,000
)
  
(1,478,000
)
         
Total liabilities and deficit
 
$
5,249,000
  
$
140,000